The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial

Table 3

Studies on the efficacy of adjunctive dopamine agonist in treatment-resistant unipolar major depressive disorder.

Study	N of subjects	Stage for treatment-resistant depression	Design	Dopamine agonist		Follow-up visit (weeks)	Efficacy (% responder)
				Drug	Dosage at endpoint (mg/day)
The present study	12	mostly stage II and III	Open-label	pramipexole	1.47±0.93	12	71^b
Inoue et al. [8]	6	stage I	Open-label	bromocriptine	40.0^a	6	67^b
Izumi et al. [9]	20	stage I	Open-label	pergolide	0.59±0.38^a	4	40^c
Sporn et al. [10]	20	stage I	Retrospective chart review	pramipexole	NA	NA	40^c
Lattanzi et al. [11]	16	stage I	Open-label	pramipexole	0.95±0.32^a	16	64^d
Cassano et al. [12]	7	stage I	Open-label	ropinirole	1.29	16	29^d
Inoue et al. [13]	10	stage II	Open-label	pramipexole	1.3±0.6^a	8	60^d

NA: not applicable.
^aMaximum dosage.
^bDefined as a reduction of 50% or more (from baseline to endpoint) in the Hamilton Depression Rating Scale total score.
^cDefined as moderate to marked improvement (from baseline to endpoint) in the Clinical Global Impression-Improvement scale.
^dDefined as a reduction of 50% or more (from baseline to endpoint) in the Montgomery-Asberg Depression Rating Scale total score.